ASND icon

Ascendis Pharma

168.01 USD
-0.83
0.49%
Updated Mar 18, 12:08 PM EDT
1 day
-0.49%
5 days
13.80%
1 month
7.57%
3 months
23.81%
6 months
12.85%
Year to date
21.75%
1 year
14.25%
5 years
70.74%
10 years
817.59%
 

About: Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America.

Employees: 1,017

0
Funds holding %
of 7,372 funds
0
Analysts bullish %
of 5 analysts

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

27% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 66

1.78% more ownership

Funds ownership: 104.07% [Q3] → 105.84% (+1.78%) [Q4]

3% less funds holding

Funds holding: 218 [Q3] → 211 (-7) [Q4]

6% less capital invested

Capital invested by funds: $9.33B [Q3] → $8.78B (-$549M) [Q4]

10% less first-time investments, than exits

New positions opened: 35 | Existing positions closed: 39

18% less funds holding in top 10

Funds holding in top 10: 17 [Q3] → 14 (-3) [Q4]

64% less call options, than puts

Call options by funds: $11.9M | Put options by funds: $32.7M

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$196
17%
upside
Avg. target
$216
29%
upside
High target
$260
55%
upside

5 analyst ratings

positive
100%
neutral
0%
negative
0%
JP Morgan
Jessica Fye
69% 1-year accuracy
27 / 39 met price target
19%upside
$200
Overweight
Maintained
18 Mar 2025
Cantor Fitzgerald
Li Watsek
26% 1-year accuracy
11 / 43 met price target
19%upside
$200
Overweight
Maintained
25 Feb 2025
Evercore ISI Group
Josh Schimmer
22% 1-year accuracy
12 / 55 met price target
55%upside
$260
Outperform
Maintained
18 Feb 2025
Goldman Sachs
Paul Choi
50% 1-year accuracy
5 / 10 met price target
34%upside
$225
Buy
Maintained
13 Feb 2025
UBS
Eliana Merle
25% 1-year accuracy
5 / 20 met price target
17%upside
$196
Buy
Initiated
7 Jan 2025

Financial journalist opinion

Neutral
GlobeNewsWire
3 weeks ago
Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference
COPENHAGEN, Denmark, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 11:10 a.m. Eastern Time / 8:10 a.m. Pacific Time in Boston, Massachusetts.
Ascendis Pharma to Participate in the TD Cowen 45th Annual Health Care Conference
Positive
Benzinga
1 month ago
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?
On Wednesday, Ascendis Pharma ASND reported a fourth-quarter EPS loss of 64 cents, beating the consensus loss of 1.07 euros.
Why Is Rare Disease Focused Ascendis Pharma Stock Trading Higher On Thursday?
Neutral
Seeking Alpha
1 month ago
Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript
Ascendis Pharma A/S (ASND) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ET Company Participants Scott Smith - Chief Financial Officer Jan Mikkelsen - President and CEO Sherrie Glass - Chief Business Officer Jay Wu - President, U.S. Market Aimee Shu - Chief Medical Officer Conference Call Participants Jessica Fye - JPMorgan Tazeen Ahmad - Bank of America Gavin Clark-Gartner - Evercore ISI Li Watsek - Cantor Fitzgerald Yaron Werber - TD Cowen Joori Park - Leerink Kelly Shi - Jefferies Ellie Merle - UBS David Lebowitz - Citi Paul Choi - Goldman Sachs Alex Thompson - Stifel Yun Zhong - Wedbush Securities Operator Good day and thank you for standing by. Welcome to the Fourth Quarter and Full Year 2024 Ascendis Pharma Earnings Conference Call.
Ascendis Pharma A/S (ASND) Q4 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
1 month ago
Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs
– Expected use of approximately $25 million in first quarter of 2025 intended to preserve approximately 200,000 ADSs held as treasury shares
Ascendis Pharma A/S Announces Share Repurchase Program & Net Settlement of Certain RSUs
Neutral
GlobeNewsWire
1 month ago
Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
– Strong early U.S. YORVIPATH ® launch with 908 prescriptions as of Feb. 7, 2025; YORVIPATH full year 2024 revenue of €28.7 million
Ascendis Pharma Reports Fourth Quarter and Full Year 2024 Financial Results
Neutral
GlobeNewsWire
1 month ago
Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025
COPENHAGEN, Denmark, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced it will report full year 2024 financial results and provide a business update on Wednesday, February 12, 2025, after the close of the U.S. financial markets. Ascendis Pharma will also host a conference call and live webcast on February 12, 2025, at 4:30 p.m. Eastern Time (ET) to discuss 2024 financial results.
Ascendis Pharma to Report Full Year 2024 Financial Results and Provide Business Update on February 12, 2025
Positive
Seeking Alpha
1 month ago
Ascendis-Novo Weight Loss Deal Highlights Technology Platform, Signals Growth Potential (Rating Upgrade)
TransCon CNP matches BioMarin's Voxzogo for achondroplasia with weekly vs daily dosing; regulatory filings planned for 2025. Commercial products Skytrofa and Yorvipath growing steadily, with Q3 revenue of $62.4M; validates TransCon platform technology. Novo deal for monthly GLP-1 in obesity could be game-changing; includes $285M in milestones plus royalties and expansion options.
Ascendis-Novo Weight Loss Deal Highlights Technology Platform, Signals Growth Potential (Rating Upgrade)
Positive
Seeking Alpha
1 month ago
Ascendis Pharma: Danish Blockbuster Hunter
Ascendis Pharma has piqued my interest due to its promising developments and strong pipeline. The company boasts several commercial stage products, indicating a robust foundation and growth potential. Ascendis' diverse pipeline supports a positive investment thesis, suggesting significant future advancements and market opportunities.
Ascendis Pharma: Danish Blockbuster Hunter
Neutral
GlobeNewsWire
2 months ago
Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference
- Ascendis positioned to drive rapid revenue growth COPENHAGEN, Denmark, Jan. 12, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today provided a business and strategic roadmap update, including planned 2025 key corporate milestones. Ascendis President and CEO Jan Mikkelsen will present this update tomorrow, January 13, during the 43rd Annual J.P.
Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference
Neutral
GlobeNewsWire
2 months ago
Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
COPENHAGEN, Denmark, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that company executives will participate in the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025, at 11:15 a.m. Eastern Time / 8:15 a.m. Pacific Time in San Francisco, California.
Ascendis Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference
Charts implemented using Lightweight Charts™